An observational study of 5800 US patients with diabetes hospitalized for heart failure benefited from starting metformin; its use was also linked with fewer future heart failure hospitalizations.
In low- to middle-income countries, SGLT2 inhibitors could reduce diabetes complications at lower but feasible prices; they are cost effective at current prices in people with heart or kidney disease.
In older adults with a hypoglycemia-related ER visit or hospitalization, insulin and/or sulfonylurea treatment was deintensified within 100 days in less than half of cases.
"Short-term hospitalization [for reasons other than diabetes] may not be the time to intervene in long-term diabetes management," researchers conclude.